(2R)-6-氧代-2-哌啶羧酸甲酯 | 183890-34-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (2R)-6-氧代-2-哌啶羧酸甲酯
• 中文别名: 2-哌啶羧酸,6-羰基-,甲基酯,(2R)-(9CI)
• 英文名称: methyl (R)-6-oxopipecolate
• 英文别名: methyl 6-oxopipecolate；methyl (R)-6-oxopiperidine-2-carboxylate；6-oxopipecolic acid methyl ester；6-oxo-piperidine-2(R)-carboxylic acid methyl ester；methyl (2R)-6-oxopiperidine-2-carboxylate
• CAS: 183890-34-8
• 化学式: C₇H₁₁NO₃
• mdl: MFCD13183953
• 分子量: 157.169
• InChiKey: UKQLYCSMIVXPDB-RXMQYKEDSA-N

物化性质

• 沸点：
  316℃
• 密度：
  1.150
• 闪点：
  145℃

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.714
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (2R)-6-氧代-2-哌啶羧酸甲酯 在 sodium tetrahydroborate 、 4-甲基苯磺酸吡啶 、 sodium hydride 、 三氟乙酸 、 potassium iodide 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.75h， 生成 6R-hydroxymethyl-1-(2-triisopropylsilanyloxy-ethyl)-piperidin-2-one
  参考文献：
  名称：

  Lactams as prostanoid receptor ligands. Part 4: 2-Piperidones as selective EP4 receptor agonists

  摘要：

  2-Piperidones were prepared bearing heptanoic acid or a thioether heptanoic acid at the I-position as well as appropriately substituted at the 6-position to mimic the structure of prostaglandins. The stereochemical purity at the 6-position was determined to be >= 95% ee for an advanced synthetic intermediate. The 2-piperidones were identified as potent agonists at the EP4 prostanoid receptor. They displayed a high affinity (K-i 5-130 nM) at EP4 and subtype selectivity. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.03.059
• 作为产物：
  描述：

  D-2-氨基己二酸 在 溶剂黄146 作用下， 生成 (2R)-6-氧代-2-哌啶羧酸甲酯
  参考文献：
  名称：

  Lactams as prostanoid receptor ligands. Part 4: 2-Piperidones as selective EP4 receptor agonists

  摘要：

  2-Piperidones were prepared bearing heptanoic acid or a thioether heptanoic acid at the I-position as well as appropriately substituted at the 6-position to mimic the structure of prostaglandins. The stereochemical purity at the 6-position was determined to be >= 95% ee for an advanced synthetic intermediate. The 2-piperidones were identified as potent agonists at the EP4 prostanoid receptor. They displayed a high affinity (K-i 5-130 nM) at EP4 and subtype selectivity. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.03.059

文献信息

• 2-Piperidone derivatives as prostaglandin agonists
  申请人：——

  公开号：US20040142969A1

  公开（公告）日：2004-07-22

  The invention provides compounds of the Formula: 1 wherein m, n, A, X, Y, Z, R 1 , R 2 , R 4 , R 6 , R 7 , R 8 , R 9 and R 10 are as defined herein, and pharmaceutically acceptable salts, solvates, prodrugs, single isomers or racemic or non-racemic mixture of isomers thereof. The invention also provides methods for preparing, compositions comprising, and methods for using compounds of formula I.

  这项发明提供了以下式的化合物： 1 其中m、n、A、X、Y、Z、R 1 、R 2 、R 4 、R 6 、R 7 、R 8 、R 9 和R 10 如本文所定义，并且其药学上可接受的盐、溶剂化合物、前药、单一异构体或其拉克米或非拉克米异构体混合物。该发明还提供了制备、包含、以及使用式I化合物的方法。
• Interrupted Pyridine Hydrogenation: Asymmetric Synthesis of δ‐Lactams
  作者：Tobias Wagener、Lukas Lückemeier、Constantin G. Daniliuc、Frank Glorius

  DOI：10.1002/anie.202016771

  日期：2021.3.15

  for increasing chemical complexity in a single reaction step. Overcoming the tenet of full reduction in arene hydrogenation has been seldom demonstrated. In this work we report the synthesis of sought‐after, enantioenriched δ‐lactams from oxazolidinone‐substituted pyridines and water by an interrupted hydrogenation mechanism.

  金属催化氢化是将容易获得的芳烃转化为饱和基序的有效方法，然而，目前的氢化策略仅限于形成C-H和N-H键。逐步添加氢气产生反应性不饱和中间体，并迅速还原。相比之下，通过不饱和中间体的进一步官能化来中断完全氢化为在单个反应步骤中增加化学复杂性提供了巨大的潜力。克服芳烃氢化完全还原的原则很少被证明。在这项工作中，我们报道了通过间断氢化机制从恶唑烷酮取代的吡啶和水合成广受欢迎的对映体富集的δ-内酰胺。
• EP4 receptor agonist, compositions and methods thereof
  申请人：——

  公开号：US20040198701A1

  公开（公告）日：2004-10-07

  This invention relates to potent selective agonists of the EP 4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.

  这项发明涉及到前列腺素E2受体EP4亚型的强效选择性激动剂，以及它们在治疗青光眼和其他与患者眼内高眼压相关的疾病中的使用或配方。此发明还涉及将本发明的化合物用于介导成骨细胞和破骨细胞的骨建模和重塑过程。
• 2-Piperidone derivatives as prostaglandin antagonists
  申请人：Elworthy Richard Todd

  公开号：US20080058375A1

  公开（公告）日：2008-03-06

  The invention provides compounds of the Formula: wherein m, n, A, X, Y, Z, R 1 , R 2 , R 4 , R 6 , R 7 , R 8 , R 9 and R 10 are as defined herein, and pharmaceutically acceptable salts, solvates, prodrugs, single isomers or racemic or non-racemic mixture of isomers thereof. The invention also provides methods for preparing, compositions comprising, and methods for using compounds of formula I.

  该发明提供了公式为：其中m，n，A，X，Y，Z，R1，R2，R4，R6，R7，R8，R9和R10的化合物的药学上可接受的盐，溶剂化合物，前药，单一异构体或其外消旋或非消旋异构体的混合物。该发明还提供了制备公式I化合物的方法，包含公式I化合物的组合物的方法，以及使用公式I化合物的方法。
• EP4 Receptor Agonist, Compositions and Methods Thereof
  申请人：Billot Xavier

  公开号：US20110237511A1

  公开（公告）日：2011-09-29

  This invention relates to potent selective agonists of the EP 4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.

  本发明涉及到前列腺素E2受体EP4亚型的有效选择性激动剂，其在治疗青光眼和其他与患者眼内压升高有关的疾病中的应用或制剂。本发明还涉及到将本发明的化合物用于介导成骨细胞和破骨细胞的骨建模和重塑过程。